Cookie policy

This site uses cookies to improve your user experience. By using this website, you agree that we can place cookies on your device. For further information, please read our Privacy And Cookies Policy

I accept the terms and conditions
Skip Ribbon Commands
Skip to main content

Clinical Evidence

 

 

Balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinomahttps://www.terumo-europe.com/en-emea/clinical-program/Clinical Data/00Hatanaka T et al World J Hepatol. 2018 Jul 27;10(7)485-495.pdfBalloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma12/03/2019 23:00:00
Dense Accumulation of Lipiodol Emulsion in Hepatocellular Carcinoma Nodule during Selective Balloon-occluded Transarterial Chemoembolization: Measurement of Balloon- occluded Arterial Stump Pressurehttps://www.terumo-europe.com/en-emea/clinical-program/Clinical Data/01 Irie T et al Cardiovasc Intervent Radiol. 2013 Jun;36(3)706-13.pdfDense Accumulation of Lipiodol Emulsion in Hepatocellular Carcinoma Nodule during Selective Balloon-occluded Transarterial Chemoembolization: Measurement of Balloon- occluded Arterial Stump Pressure12/03/2019 23:00:00
Balloon-occluded transarterial chemoembolization using a 1.8-French tip Coaxial microballoon catheter for hepatocellular carcinoma: Technical and safety considerationshttps://www.terumo-europe.com/en-emea/clinical-program/Clinical Data/02 Matsumoto T et al Minim Invasive Ther Allied Technol. 2015 Apr;24(2)94-100.pdfBalloon-occluded transarterial chemoembolization using a 1.8-French tip Coaxial microballoon catheter for hepatocellular carcinoma: Technical and safety considerations12/03/2019 23:00:00
Efficacy of a microballoon catheter in transarterial chemoembolization of hepatocellular carcinoma using miriplatin, a lipophilic anticancer drug: Short-term resultshttps://www.terumo-europe.com/en-emea/clinical-program/Clinical Data/03 Ogawa M et al Hepatol Res. 2016 Mar;46(3)E60-9.pdfEfficacy of a microballoon catheter in transarterial chemoembolization of hepatocellular carcinoma using miriplatin, a lipophilic anticancer drug: Short-term results12/03/2019 23:00:00<p>​<span style="font-size:11pt;font-family:calibri;color:black;">Masahiro</span><span style="font-size:11pt;font-family:calibri;color:black;"> Ogawa, </span><span style="font-size:11pt;font-family:calibri;color:black;">Kentaro</span><span style="font-size:11pt;font-family:calibri;color:black;"> </span><span style="font-size:11pt;font-family:calibri;color:black;">Takayasu</span><span style="font-size:11pt;font-family:calibri;color:black;">, Midori </span><span style="font-size:11pt;font-family:calibri;color:black;">Hirayama</span><span style="font-size:11pt;font-family:calibri;color:black;">, </span><span style="font-size:11pt;font-family:calibri;color:black;">Takao</span><span style="font-size:11pt;font-family:calibri;color:black;"> </span><span style="font-size:11pt;font-family:calibri;color:black;">Miura</span><span style="font-size:11pt;font-family:calibri;color:black;">, </span><span style="font-size:11pt;font-family:calibri;color:black;">Katsuhiko</span><span style="font-size:11pt;font-family:calibri;color:black;"> </span><span style="font-size:11pt;font-family:calibri;color:black;">Shiozawa</span><span style="font-size:11pt;font-family:calibri;color:black;">, </span><span style="font-size:11pt;font-family:calibri;color:black;">Masahisa</span><span style="font-size:11pt;font-family:calibri;color:black;"> Abe, </span><span style="font-size:11pt;font-family:calibri;color:black;">Naoki</span><span style="font-size:11pt;font-family:calibri;color:black;"> Matsumoto, Hiroshi </span><span style="font-size:11pt;font-family:calibri;color:black;">Nakagawara</span><span style="font-size:11pt;font-family:calibri;color:black;">, Shu </span><span style="font-size:11pt;font-family:calibri;color:black;">Ohshiro</span><span style="font-size:11pt;font-family:calibri;color:black;">, </span><span style="font-size:11pt;font-family:calibri;color:black;">Toshiki</span><span style="font-size:11pt;font-family:calibri;color:black;"> Yamamoto, </span><span style="font-size:11pt;font-family:calibri;color:black;">Naohide</span><span style="font-size:11pt;font-family:calibri;color:black;"> Tanaka, </span><span style="font-size:11pt;font-family:calibri;color:black;">Mitsuhiko</span><span style="font-size:11pt;font-family:calibri;color:black;"> </span><span style="font-size:11pt;font-family:calibri;color:black;">Moriyama</span><span style="font-size:11pt;font-family:calibri;color:black;">, </span><span style="font-size:11pt;font-family:calibri;color:black;">Haruomi</span><span style="font-size:11pt;font-family:calibri;color:black;"> </span><span style="font-size:11pt;font-family:calibri;color:black;">Mutou</span><span style="font-size:11pt;font-family:calibri;color:black;">, </span><span style="font-size:11pt;font-family:calibri;color:black;">Yoshinobu</span><span style="font-size:11pt;font-family:calibri;color:black;"> Yamamoto and </span><span style="font-size:11pt;font-family:calibri;color:black;">Toshiyuki</span><span style="font-size:11pt;font-family:calibri;color:black;"> </span><span style="font-size:11pt;font-family:calibri;color:black;">Irie</span><br></p>
Safety and efficacy of balloon-occluded transcatheter arterial chemoembolization using miriplatin for hepatocellular carcinomahttps://www.terumo-europe.com/en-emea/clinical-program/Clinical Data/04 Arai H et al Hepatol Res. 2015 Jun;45(6)663-6.pdfSafety and efficacy of balloon-occluded transcatheter arterial chemoembolization using miriplatin for hepatocellular carcinoma12/03/2019 23:00:00